Scaling cell therapy manufacturing without compromising quality: Rethinking compliance, digitalization, and GMP
04 May 2026
Cell Therapy Manufacturing
- Using connected data to reduce risk and speed release: How can real-time visibility across manufacturing, quality, and documentation improve traceability, comparability, and audit readiness while shortening review and release cycles?
- From paper-heavy to digitally connected manufacturing: Where are CGT manufacturers seeing the most immediate impact from digitizing manufacturing and quality processes, and where does manual execution still hold teams back?
- Preparing for scale and global operations: As therapies move toward commercialization and global distribution, what systems, data strategies, and operating models are critical to scaling without increasing risk or overhead?
